News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Artegraft, Inc. Release: 3-Year Prospective, Randomized Clinical Study at Massachusetts General Hospital Confirms Superiority of Artegraft to Cuffed Eptfe for Hemodialysis Access


6/21/2011 11:09:01 AM

June 21, 2011 -- ePTFE (North Brunswick, NJ) The Journal of Vascular Surgery, in its June 2011 issue, has published the clinical results of a three-year prospective, randomized study comparing Artegraft® (Bovine Carotid Artery) to Bard® Venaflo® for hemodialysis access.

The study’s conclusion: The BCA graft is an excellent option for patients on hemodialysis that are not eligible for native arteriovenous fistulas, as these grafts required fewer interventions than the ePTFE grafts to maintain patency.

Artegraft vs Venaflo:

Overall Primary Patency Rate at 1 Year 60% vs10% Assisted Primary Patency Rate at 1 Year 60% vs 20% Assisted Primary Patency Rate at 2 Years 40% vs 14% Less Thrombosis, Fewer Interventions and No Pseudoaneurysms with BCA.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES